Thulium Laser and Growth Factors for Androgenetic Alopecia - a Prospective, Clinical Study

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Men and women aged 18 and over

• Good general health, no relevant previous illnesses

• Presence of an AGA

• Cognitive ability and willingness to give consent (informed consent)

• Be willing and able to attend follow-up visits

Locations
Other Locations
Germany
University Medical Center Hamburg-Eppendorf
RECRUITING
Hamburg
Contact Information
Primary
Lynhda Nguyen, Dr. med.
l.nguyen@uke.de
+49 (0)40 7410 54289
Time Frame
Start Date: 2023-12-01
Estimated Completion Date: 2025-10-01
Participants
Target number of participants: 30
Treatments
Active_comparator: Thulium laser + growth factor serum + LED
Thulium laser + growth factor serum + LED
Active_comparator: Thulium laser + growth factor serum
Thulium laser + growth factor serum
Active_comparator: Thulium laser
Thulium laser
Related Therapeutic Areas
Sponsors
Leads: Universitätsklinikum Hamburg-Eppendorf

This content was sourced from clinicaltrials.gov